Last reviewed 2026-04-20 · How we verify
Home › Drugs › Imperial College Healthcare NHS Trust › Evolocumab Auto-Injector [Repatha] Evolocumab Auto-Injector [Repatha]
At a glance
Generic name Evolocumab Auto-Injector [Repatha] Also known as Repatha Sponsor Imperial College Healthcare NHS Trust Modality Small molecule Phase FDA-approved
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/evolocumab-auto-injector-repatha · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.